HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Martin Griesshammer Selected Research

anagrelide (Agrylin)

9/2021Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet.
1/2018Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.
1/2017Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
4/2014Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.
6/2009Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Martin Griesshammer Research Topics

Disease

18Neoplasms (Cancer)
02/2022 - 06/2005
14Polycythemia Vera
11/2021 - 11/2003
10Primary Myelofibrosis (Myelosclerosis)
11/2021 - 05/2004
9Splenomegaly
07/2022 - 02/2011
8Hemorrhage
02/2022 - 05/2004
8Essential Thrombocythemia
05/2021 - 10/2005
7Thrombocytopenia (Thrombopenia)
07/2022 - 01/2015
7Anemia
01/2020 - 02/2011
5Thrombosis (Thrombus)
08/2021 - 06/2006
4Infections
10/2020 - 01/2015
3Thrombocytosis (Thrombocythemia)
07/2022 - 09/2021
3Leukemia
01/2018 - 01/2013
3BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
06/2007 - 05/2004
2Hypertension (High Blood Pressure)
07/2022 - 08/2021
2Adenocarcinoma
02/2022 - 03/2020
2Lymphoma (Lymphomas)
04/2019 - 10/2018
2Polycythemia (Erythrocytosis)
01/2019 - 11/2003
1Leukocytosis (Pleocytosis)
04/2022
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/2022
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
02/2022
1Sickle Cell Anemia (Hemoglobin S Disease)
12/2021
1von Willebrand Diseases (von Willebrand's Disease)
09/2021
1Liver Diseases (Liver Disease)
06/2021
1Renal Insufficiency (Renal Failure)
06/2021
1Thrombophilia
06/2021
1Spontaneous Abortion (Miscarriage)
05/2021
1Second Primary Neoplasms (Neoplasms, Second)
01/2020
1B-Cell Lymphoma (Lymphoma, B Cell)
04/2019
1Hypoxia (Hypoxemia)
01/2019
1Lung Diseases (Lung Disease)
01/2019
1Skin Neoplasms (Skin Cancer)
01/2019
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
07/2018
1Transient Ischemic Attack
01/2018
1Ischemic Stroke
01/2018
1Leukopenia
12/2017
1Fatigue
01/2017
1Headache (Headaches)
01/2017
1Dyspnea (Shortness of Breath)
01/2017
1Dizziness (Lightheadedness)
01/2017
1Nausea
01/2017
1Angina Pectoris
01/2017
1Sleepiness
01/2017
1Pruritus (Itching)
08/2016
1Venous Thrombosis (Deep-Vein Thrombosis)
01/2016
1Herpes Zoster
01/2015
1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
01/2013
1Heart Failure
01/2013
1Myocardial Infarction
01/2013
1Portal Hypertension
02/2011
1Fibrosis (Cirrhosis)
05/2009
1Hyperplasia
05/2009
1hereditary Thrombophilia
06/2006
1Myeloproliferative Disorders (Myeloproliferative Disorder)
10/2005

Drug/Important Bio-Agent (IBA)

19ruxolitinibIBA
07/2022 - 01/2015
13Hydroxyurea (Hydrea)FDA LinkGeneric
07/2022 - 05/2004
5anagrelide (Agrylin)FDA LinkGeneric
09/2021 - 06/2009
5Janus Kinase 2IBA
03/2020 - 10/2005
4Janus KinasesIBA
07/2022 - 01/2015
4Janus Kinase InhibitorsIBA
04/2018 - 01/2016
4InterferonsIBA
04/2018 - 05/2004
4Syntex adjuvant formulationIBA
12/2017 - 11/2012
3AnticoagulantsIBA
02/2022 - 08/2021
3Pharmaceutical PreparationsIBA
12/2021 - 06/2007
3Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
05/2021 - 01/2016
3Imatinib Mesylate (Gleevec)FDA Link
07/2013 - 05/2004
2Janus Kinase 1IBA
10/2021 - 01/2016
2Interferon-alpha (Interferon Alfa)IBA
09/2021 - 05/2021
2Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA
06/2021 - 05/2021
2Rituximab (Mabthera)FDA Link
04/2019 - 10/2018
2Pipobroman (Vercyte)FDA Link
01/2019 - 01/2017
2N- (cyanomethyl)- 4- (2- ((4- (4- morpholinyl)phenyl)amino)- 4- pyrimidinyl)benzamideIBA
12/2017 - 01/2017
2Immunologic Factors (Immunomodulators)IBA
01/2017 - 02/2011
2Tyrosine Kinase InhibitorsIBA
07/2013 - 01/2013
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
08/2021
1Uric Acid (Urate)IBA
08/2021
1Doxorubicin (Adriamycin)FDA LinkGeneric
04/2019
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
04/2019
1Vincristine (Oncovin)FDA LinkGeneric
04/2019
1Prednisone (Sone)FDA LinkGeneric
04/2019
1vinyltriethoxysilane (VTES)IBA
01/2019
1NicotineFDA Link
01/2019
1Drug CombinationsIBA
01/2019
1Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
10/2018
1TabletsIBA
04/2018
1Hemoglobins (Hemoglobin)IBA
01/2018
1CalreticulinIBA
12/2017
1diethylstilbestrol monophosphate (PDES)IBA
01/2013
1Adrenal Cortex Hormones (Corticosteroids)IBA
02/2011
1HematinicsIBA
02/2011
1AndrogensIBA
02/2011
1Reticulin (Reticular Fiber)IBA
05/2009

Therapy/Procedure

35Therapeutics
07/2022 - 05/2004
3Drug Therapy (Chemotherapy)
04/2022 - 06/2005
2Erythrocyte Transfusion
12/2017 - 01/2017
1Indwelling Catheters (Indwelling Catheter)
06/2021
1Curettage
05/2021
1Stem Cell Transplantation
01/2018
1Splenectomy
02/2011
1Homologous Transplantation
06/2007
1Hematopoietic Stem Cell Transplantation
06/2007